Alkermes plc executive David Joseph Gaffin, EVP and Chief Legal Officer of Alkermes, Inc., reported an open-market sale of 2,034 Ordinary Shares at $33.20 per share. The transaction was made under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person. Following this sale, he continues to hold 231,558 Ordinary Shares directly, indicating a substantially larger remaining equity position in the company.
Alkermes plc reported a Form 144 disclosure showing sales of Common Stock by an issuer-associated holder. The filing lists three reported sales on 03/02/2026, 03/03/2026, and 04/06/2026 with amounts 59,575.86, 60,531.84, and 70,315.38 respectively. The record also lists earlier vesting events for restricted stock units and performance share units (355; 844; 776; 59) from 2017–2018.
Alkermes plc EVP R&D and Chief Medical Officer Craig C. Hopkinson exercised employee stock options for 5,000 ordinary shares at $19.34 per share and then sold 9,000 ordinary shares at a weighted average price of $33.3955 on May 1, 2026.
Both the option exercise and the open-market sale were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 14, 2025. After these transactions, Hopkinson directly held 81,389 ordinary shares, and the exercised options are fully vested in accordance with their terms.
Alkermes plc has amended its prior acquisition filing to add full financial statements for its new subsidiary, Avadel Pharmaceuticals plc, and pro forma combined results. The amendment includes audited Avadel financials for the three years ended December 31, 2025 and Alkermes’ unaudited pro forma condensed combined balance sheet and income statement for 2025.
Avadel’s 2025 results show net product revenue of $279.1 million, up sharply from prior years, driven entirely by narcolepsy drug LUMRYZ. Net income was $64.7 million in 2025 versus losses in 2024 and 2023, while cash and cash equivalents rose to $165.4 million at year-end 2025. Total assets were $285.1 million and shareholders’ equity was $171.3 million.
The notes detail the October 2025 transaction agreement under which Alkermes acquired all Avadel shares for $21.00 per share in cash plus a non-transferable $1.50 per-share contingent value right, and Avadel’s subsequent delisting. They also highlight LUMRYZ’s U.S. approvals, orphan drug exclusivity into 2030 and 2031 for adult and pediatric narcolepsy, a 2025 license deal for sleep-disorder candidate valiloxybate with a $20.0 million upfront payment, and a 2023 royalty financing that carried a 25.4% effective interest rate and a $37.1 million year-end obligation.
Alkermes plc reports insider share dispositions and planned transactions involving ordinary shares. Craig Hopkinson reported three past dispositions of 9,000 shares each on 02/02/2026, 03/02/2026 and 04/01/2026. The filing also lists a broker-assisted cashless exercise for 5,000 shares on 05/01/2026 and vesting of a performance share award of 4,000 shares on 02/05/2026.
Alkermes PLC ownership disclosure: Vanguard Portfolio Management reports beneficial ownership of 9,647,056 shares of Alkermes PLC common stock, representing 5.8% of the class. The filing shows sole dispositive power over 9,647,056 shares and sole voting power over 135,944 shares. The statement attributes holdings to Vanguard Portfolio Management LLC and affiliated divisions.
Alkermes PLC ownership disclosure: Vanguard Capital Management reports beneficial ownership of 8,676,888 shares of Alkermes common stock, representing 5.21% of the class as reported. The filing shows 1,249,491 shares with sole voting power and 8,676,888 shares with sole dispositive power. The disclosure is signed by Ashley Grim.
Alkermes plc. director Nancy Lurker reported a routine equity compensation event. She exercised a restricted stock unit award covering 3,751 ordinary shares, converting it into the same number of ordinary shares at a stated price of $0.00 per share.
Of these shares, 901 ordinary shares were withheld at $33.36 per share to cover tax obligations related to the vesting, leaving her with 13,555 ordinary shares held directly after the transactions. The restricted stock units vest in three equal annual installments beginning on April 11, 2025.
Alkermes plc. executive David Joseph Gaffin, EVP and Chief Legal Officer of Alkermes, Inc., reported an open-market sale of company ordinary shares. He sold 2,034 Ordinary Shares at an average price of $34.57 per share. After this transaction, he directly holds 233,592 Ordinary Shares, indicating the sale was a small portion of his overall position. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person.